Delivery Order SPE2DB24D2013-SPE2DB25FCJUA
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 50 mg capsules (100-count units) valued at $1,876.30 under a firm fixed price contract type. The award, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-competitive delivery order executed against AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $2,735.43 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 10 mg on July 29, 2025, with completion scheduled for July 30, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is executed as a child order under AmerisourceBergen's larger prime contract vehicle. The pharmaceutical product will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a contract value of $1,552.17. This competitively awarded, non-set-aside delivery order is structured as a firm fixed price contract with an ultimate completion date of July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $1,241.46 to AmerisourceBergen Drug Corp for Vyvanse 40 mg capsules (100-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside delivery order for pharmaceutical supply to support federal medical procurement needs. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a $2,468.26 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 40 mg, with performance completion targeted for July 31, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The product will be delivered to the contractor's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) under a firm fixed-price contract valued at $1,927.86. The order was competitively awarded without set-aside designation and is scheduled for completion by July 31, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location and serve as the prime contractor on this delivery order, which...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) with a contract value of $6,400.76. This competitively awarded, firm fixed price delivery order was issued on July 28, 2025, with an ultimate completion date of July 29, 2025. The contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100 count) on July 23, 2025, with a ceiling value of $1,456.54 and an ultimate completion date of July 24, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) at a ceiling value of $2,079.25. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025. The award represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends...
- The Defense Logistics Agency awarded a delivery order valued at $1,456.80 to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100-count units) on July 29, 2025, with an ultimate completion date of July 30, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen Drug Corp's broader Indefinite Delivery...
- SPE2DB24D2013Indefinite Delivery Contract
- SPE2DB24D2013-SPE2DB25FCJUADelivery Order
The Defense Logistics Agency awarded a $1,014.87 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Vyvanse 50 mg, with performance to be completed by August 1, 2025. This competitively awarded, firm fixed-price contract was issued with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's existing contract vehicle to supply pharmaceutical products and medical commodities to federal healthcare systems. This award is a child order issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999.9 billion pharmaceutical support vehicle valued through December 2026. The IDC enables AmerisourceBergen to serve as a primary pharmaceutical distributor for military healthcare programs, the Defense Health Agency, U.S. Coast Guard, and other federal government healthcare systems on a global basis. The Vyvanse delivery represents one of numerous pharmaceutical orders fulfilled through this framework, which encompasses brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 7/31/25 |